Rani Therapeutics eyes potential IPO as robotic pill technology takes shape
Two efforts to transform injectables into robotic pills — a colossal market designed to enhance treatment compliance, diminish the need for physician-led therapeutic administration and placate needle-phobic patients — got off the ground last year. Now, one of these initiatives, led by an inventor who played an influential role in pioneering the first FDA-approved automatic implantable cardioverter defibrillator (ICD) has taken another key step in its quest with a successful early-stage efficacy and safety study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.